Synaptogenix, Inc. (SNPX)
Largest Insider Buys in Sector
SNPX Stock Price History Chart
SNPX Stock Performance
About Synaptogenix, Inc.
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; …
Insider Activity of Synaptogenix, Inc.
Over the last 12 months, insiders at Synaptogenix, Inc. have bought $0 and sold $0 worth of Synaptogenix, Inc. stock.
On average, over the past 5 years, insiders at Synaptogenix, Inc. have bought $165,600 and sold $190,375 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $83,000 was made by Silverman Joshua (director) on 2021‑06‑14.
List of Insider Buy and Sell Transactions, Synaptogenix, Inc.
| 2022-12-16 | Sale | director | 19,012 0.2656% | $1.17 | $22,280 | -30.83% | ||
| 2022-12-16 | Sale | President and CSO | 19,688 0.2751% | $1.17 | $23,072 | -30.83% | ||
| 2022-12-16 | Sale | Chief Financial Officer | 27,000 0.3773% | $1.17 | $31,641 | -30.83% | ||
| 2022-12-16 | Sale | Chief Executive Officer | 27,000 0.3773% | $1.17 | $31,641 | -30.83% | ||
| 2022-12-16 | Sale | director | 27,000 0.3773% | $1.17 | $31,641 | -30.83% | ||
| 2022-12-16 | Sale | director | 20,250 0.2829% | $1.17 | $23,731 | -30.83% | ||
| 2022-12-16 | Sale | director | 22,500 0.3144% | $1.17 | $26,368 | -30.83% | ||
| 2021-06-14 | director | 10,000 0.2577% | $8.30 | $83,000 | -3.58% | |||
| 2021-06-14 | Chief Scientific Officer | 10,000 0.2565% | $8.26 | $82,600 | -3.58% |
Insider Historical Profitability
| Silverman Joshua | director | 38238 2.8207% | $2.47 | 1 | 1 | <0.0001% |
| Alkon Daniel L. | President and CSO | 35546 2.6221% | $2.47 | 1 | 1 | <0.0001% |